Recombinant Human CLDN18.2 (N-Twin strep-Flag)

Description

EnkiLife provides the Recombinant Human CLDN18.2 (N-Twin strep-Flag) protein,aslo know as Claudin-18.2,CLDN18.2,CLDN18,Claudin-18,Claudin 18.2, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human CLDN18.2 is produced by our Mammalian expression system and the target gene encoding Met1-Ala200 is expressed with a Twin strep, Flag tag at the N-terminus.The product is not recommended for cell based experiments. *The product is not recommended for cell based experiments.Accession:P56856-2. Expression Host:Human cells.Species:Human.Predicted Molecular Mass:25.5 kDa. Background:Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas，while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.